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ABSTRACT
Purpose To eva lua te pharmacok ine t i c pro f i l e ,
biodistribution and therapeutic effect of cationic
thermosensitive liposomes (CTSL) encapsulating doxorubicin
(Dox) upon mild hyperthermia (HT).
Methods Non-targeted thermosensitive liposomes (TSL) and
CTSL were developed, loaded with Dox and characterized.
Blood kinetics and biodistribution of Dox-TSL and Dox-
CTSL were followed in B16BL6 tumor bearing mice upon
normothermia (NT) or initial hyperthermia conditions. Effi-
cacy study in B16BL6 tumor bearing mice was followed with
Dox-TSL or Dox-CTSL upon NT or HT. Efficacy study in
LLC tumor bearing mice was performed upon two HT con-
ditions. Intravital microscopy was performed on B16BL6 tu-
mors implanted in dorsal-skin fold window-bearing mice.
Results Targeting did not cause faster blood clearance of
CTSL compared to TSL. Highest uptake of liposomes was
observed in spleen, kidneys and liver. Applying HT prior to
CTSL administration increased drug delivery to the tumor
and CTSL delivered ~1.7 fold higher Dox concentration
compared to TSL. Efficacy in B16BL6 murine melanoma
showed that HT had a significant effect on CTSL in tumor
suppression and prolonged survival. Efficacy in LLC Lewis
lung carcinoma tumor model demonstrates that two HT
treatments hold promises for a successful treatment option.
Conclusion CTSL have potency to increase drug efficacy in
tumors due to their targeted and drug release functions.
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DSPC 1,2-distearoyl-sn-glycero-
3- phosphatidylcholine
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3-phosphoethanolamine-
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FCS Fetal calf serum
Fig. Figure
GFP Green fluorescence protein
H Hours
HEPES 4-(2-hydroxyethyl)-1-
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HT Hyperthermia
i.v. Intravenous
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NT Normothermia
S.c. Subcutaneous
SD Standard deviation
SEM Standard error
TSL Thermosensitive
liposomes
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INTRODUCTION
Liposomes as one of the best studied nanocarriers for treat-
ment of cancer improve pharmacokinetics and biodistribution
of the encapsulated chemotherapeutic drugs after systemic
administration (1). Despite their prolonged blood circulation,
in the clinic, pegylated limosomal doxorubicin has only limit-
ed therapeutic efficacy (2,3) due to its low tumor retention and
low drug bioavailability (4–6). An idea to improve this in-
cludes targeting of liposomes with specific ligands for in-
creased tumor retention together with an external trigger,
i.e., heat, which can increase drug delivery locally in the tumor
area while preventing the healthy tissues from side effects. The
aim of this study was to use cationic thermosensitive liposomes
(CTSL) (7) loaded with doxorubicin (Dox), which combine
both targeted and triggered characteristics of liposomes in
one carrier in order to deal with the drawbacks of the liposo-
mal chemotherapy and follow their behaviour in vivo. The
designed nanoparticles made use of shielded cationic lipids
for specific recognition of tumor vasculature and tumor cells
in combination with thermosensitive lipid bilayers for heat-
triggered drug release.
In the clinic, mild hyperthermia (HT) is known to increase
the effect of chemo- and radiotherapy leading to enhanced
therapeutic efficacy in cancer patients (8,9). Mild hyperther-
mia can inhibit DNA repair, augment tissue oxygenation and
sensitize cancer cells to cytotoxic drugs (10,11). Additionally,
HT is able to increase blood flow and interstitial fluid flow
helping an enhanced passive perfusion of small molecules.
More importantly, HT can increase nanoparticle extravasa-
tion by increasing the gaps between the vascular endothelial
cells (12–14). In addition, HT can trigger drug release locally
in the tumor (13,15–18). Previous studies have shown in-
creased therapeutic effect from thermosensitive liposomes
(TSL) triggered with mild HT. The effect was mostly due to
extravasation and increased drug release locally in the tumor
(18–22).
Another approach for improved drug bioavailability comes
from active targeting of liposomes to the tumor. Decorating
liposomes with ligands specific for tumor vasculature or tumor
cells may result in their higher retention in tumors and subse-
quently increased drug delivery.
Cationic liposomes are known to specifically bind angio-
genic endothelial and tumor cells due to the increased expres-
sion of negatively charged molecules on these cell membranes
(23). The slower and irregular blood flow in tumors also pro-
motes binding between passing cationic liposomes and tumor
vasculature (24). The specific binding of CTSL to either en-
dothelial or tumor cells may lead to receptor-mediated endo-
cytosis of the carrier, therefore bringing the drug closer to the
nucleus. CTSL are also composed of thermosensitive lipids
with a large capacity to encapsulate drugs and release them
upon heat. When HT is applied, CTSL lipid membrane
undergoes gel-to-liquid crystalline phase transition and be-
comes more permeable towards water and solutes (25). In this
way, the encapsulated hydrophilic drugs can be released
intracellularly.
The therapeutic effect of HT together with TSL was inves-
tigated in many preclinical studies (19,22,26–35). A major
drawback of these studies is the lack of uniform experimental
setup, conditions and read-out.
Several TSL formulations have been studied (36). Al-Jamal
e t al . reported detai led on pharmacokinetics and
biodistribution of different TSL in presence or absence of
HT showing that TSL stability and make-up affect drug de-
livery and intratumoral availability (37). An optimum HT
protocol requires knowledge on pharmacokinetics,
biodistribution and tumor accumulation of the liposomal
nanocarriers as HTmay become a treatment option for many
types of cancer. However, detailed understanding of the phar-
macological behaviour of targeted thermosensitive liposomes
is not available yet.
In this study, the pharmacokinetics, biodistribution and
therapeutic efficacy of doxorubicin encapsulated in cationic
thermosensitive liposomes (CTSL) were investigated. For the
efficacy studies, we tested the tumor growth of two different
types of tumors - B16BL6 murine melanoma and LLC Lewis
lung carcinoma over time. The tumor growth of two groups—
TSL and CTSL was studied with or without HT in B16BL6
or with two HT treatments in LLC . PBS was used as a
control.
MATERIALS & METHODS
Chemicals
The phosphol ipids 1,2-dipalmitoyl- sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were
purchased from Lipoid (Ludwigshafen, Germany). The cat-
ionic lipid 1,2-dipalmitoyl-3-trimethylammonium-propane
(DPTAP Chloride salt) was from Avanti Polar Lipid Inc.
Doxorubicin-HCl was purchased from Pharmachemie (Haar-
lem, The Netherlands). Sodium 3′-[(1-phenylaminocarbonyl)-
3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid
hydrate (XTT) was purchased from Sigma-Aldrich
(Zw i j nd r e ch t , The Ne th e r l and s ) . D i o c t ade c y l
tetramethylindotricarbocyanine perchlorate (DiD-C18(3))
was purchased from Invitrogen.
Preparation of TSL
CTSL were composed of DPPC:DSPC:DPTAP:DSPE-
PEG2000 in a molar ratio 62.5:25:7.5:5. TSL consisted of
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DPPC:DSPC:DSPE-PEG2000 in a molar ratio 70:25:5 All
the liposomes were prepared by lipid film hydration and ex-
trusion method. The lipids were dissolved in chloroform and
methanol (9:1 vol/vol). Liposomes used for intravital micros-
copy contained 0.3% of DiD. The solvent was subsequently
evaporated under vacuum in rotary evaporator until homo-
geneous lipid film was formed. The lipid film was hydrated in
250 mM (NH4)2SO4 solution at 60°C for 30 min. The newly
formed multilammelar vesicles were extruded subsequently
five times through 100 nm, five times through 80 nm and five
times through 50 nm polycarbonate filter (thermo barrel ex-
truder at 60°C) and resulted in small sized TSL.
Extraliposomal (NH4)2SO4 was removed from liposomal
(NH4)2SO4 by gel permeation chromatography using a PD-
10 Sephadex column (GE Healthcare, Buckinghamshire,
UK), eluted with HEPES buffer, pH 7.4 (10 mM HEPES,
135 mM NaCl). Size, polydispersity index (PDI) and zeta po-
tential (ζ) were measured by dynamic light scattering using
Zetasizer Nano ZS (Malvern Instruments, Worcestershire,
UK). For size and PDI measurements, TSL were diluted in
HEPES, pH 7.4, while the zeta potential was obtained in
HEPES, pH 7 without NaCl. Lipid concentration was deter-
mined by phosphate assay (38). After the phosphate concen-
tration was determined, doxorubicin was loaded into the lipo-
somes (5 mM lipid) in 0.05:1 drug:lipid ratio (mol:mol) at
38°C for 1 h. The liposomes were concentrated by ultracen-
trifugation for 2 h, 4°C. The pellet was resuspended in
HEPES buffer, pH 7.4 and left overnight on slow rotation at
4°C. Then the liposomes were passed through PD 10 column
eluted with HEPES buffer, pH 7.4 to remove residual
nonentrapped doxorubicin. Doxorubicin concentration was
measured by spectrophotometer at Ex 480 nm.
Cell Lines and Culture
Tumor cell lines B16 (murine melanoma) and LLC (Lewis
lung carcinoma) were cultured in a Dulbecco’s Modified Ea-
gles’ medium (Lonza, Belgium) containing 10% FCS. Cells
were subcultured once a week using Trypsin (Sigma, Aldrich)
and maintained at 37°C, 5% CO2 in a humidified incubator.
All experiments were performed at a confluence of 80–90%.
Animal Models
The eNOStag-GFP mice line in which the endothelial cells
are visible due to constitutive expression of a GFP eNOS-tag
fusion protein was used for intravital imaging. Mice weighing
about 25 g were used and fed a standard laboratory diet ad
libitum (Hope Farms Woerden, The Netherlands). All animal
experiments were done in accordance with the Dutch law and
protocols were approved by the committee on animal exper-
imentation of the Erasmus MC, Rotterdam, the Netherlands.
Preparation of the dorsal skin-fold chamber with B16BL6
tumor is an adaptation from previously described procedures
(13,18,19). The mice were housed in an incubation room with
an ambient temperature of 30°C and a humidity of 70%.
Experiments started 8 to 12 days after tumor implantation,
at which a functional vasculature is established in the tumor.
For in vivo efficacy study, ~ a 3 mm3 tumor piece of either
B16BL6 or LLC tumors was implanted in the hind limb of
C57BL6 mice. Mice were used for experiments when tumors
reached ~5 mm in diameter.
Intravital Microscopy for Dox and Liposome Retention
in B16BL6 Tumors
DiD-labelled TSL or CTSL containing Dox were injected i.v.
(5 mg/kg Dox) and let to circulate in the blood stream for 5 h
in order to allow for liposome targeting to tumor vasculature.
After the targeting phase, HT at 42°C for 1 h was applied to
trigger drug release from the liposomes. Mice were observed
by confocal microscopy (Zeiss LSM 510 META) up to 120 h
after injection of Dox-TSL or Dox-CTSL in order to visualize
Dox and liposome clearance from the tumor. Images of
1024×1024 pixels were analyzed using Zeiss LSM image soft-
ware (Zeiss, Germany), 10× objective lens. Doxorubicin fluo-
rescence was detected by a 543 nm Helium –Neon laser and
DiD fluorescence by 613 nm nm Helium –Neon laser.
Pharmacokinetic and Biodistribution of Dox-TSL
and Dox-CTSL
Pharmacokinetics and biodistribution of Dox-TSL and Dox-
CTSL were followed in B16BL6 tumor bearing mice upon
NT or initial HT conditions. At NT condition, mice were
injected with 3 mg/kg Dox and blood sampling was per-
formed at 0.1;1;2;4;6 and 24 h and organs were collected
24 h after liposome injection. At HT condition, tumors were
first preheated for 1 h at 41°C and then cooled down for
15 min, in order to facilitate liposome extravasation. Then,
liposomes were injected at 3 mg/kg Dox and blood samples
were collected up to 24 h (0.1;1;2;6;24 h), after which the
organs were removed. Blood samples (~50 μL/sample), pieces
of organs (~100 mg/organ) and complete tumors obtained
during the blood kinetics and biodistribution experiments
were analyzed for their doxorubicin concentrations. To all
samples, an aqueous solution of daunorubicin (0.5 μg/mL in
1.5 mL H2O) was added as an internal standard for doxoru-
bicin quantification, followed by homogenization for 5–
20 min at 30 Hz in a Qiagen Tissuelyser. In order to extract
doxorubicin, 125 μL of the homogenized blood and tissue
solutions was incubated with 50 μL AgNO3 in water (33%
w/v) for 10min at room temperature. Subsequently, the doxo-
rubicin was extracted by vigorous mixing with 1.25 mL
chloroform/isopropanol (2:1 v/v). After centrifugation
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(10 min at 3600 rpm) the organic phase was transferred to a
clean tube and evaporated to dryness at 40°C under N2 flow.
The residue was dissolved in H2O (200 μL) of which 50 μL
was injected onto the HPLC column. HPLC analysis was
performed on an Agilent Technologies system (1100 series)
equipped with an autosampler and fluorescence detector
(λex=485 nm and λem=590 nm). An Eclipse XDB-C18 col-
umn (5 μm, 4.6×150 mm2 Agilent) was used. The doxorubi-
cin and daunorubicin were eluted in 6 and 12 min respective-
ly, using an isocratic flow of 1 mL/min with 30% (v/v) aceto-
nitrile in H2O containing 0.1% TFA (v/v). The Dox concen-
tration in blood and organs was calculated as % injected
dose/g tissue (%ID/g). Six mice were used per each group.
Therapeutic Efficacy of Dox-TSL and Dox-CTSL
in B16BL6 and LLC Tumors
C57Bl6 mice were implanted s.c. with B16BL6 murine mela-
noma or murine LLC Lewis lung carcinoma in their hind
limbs. When tumor size reached 5mm in diameter, mice were
anesthetized and the tumor bearing hind legs except the tu-
mor were covered with vaseline to protect them from direct
heat. The tumor was in direct contact with the water bath.
The hind legs were fixed on a rack to ensure a steady position
in a water bath during the HT treatment. Thermocouples
were attached to the tumor surface at multiple spots to mon-
itor tumor temperature over time. The water bath tempera-
ture was set to 43°C to reach tumor temperature at 42°C. In
B16BL6 bearing mice, mice were injected with PBS, Dox-
TSL and Dox-CTSL (3 mg/kg Dox) and 5 h later HT at
42°C for 1 h was applied to trigger drug release. Mice with
PBS, Dox-TSL and Dox-CTSL under NT were used as con-
trol groups. In LLC bearing mice, there was an initial HT
treatment for 1 h at 41°C followed by a cool down for
15 min. Then, liposomes were injected and allowed to circu-
late for 5 h. A second HT for 1 h at 42°C was then applied to
trigger drug release. After the treatment, the mice were
returned back to the cages. The tumor size and the body
weight were measured on the day of the experiment and every
other day after the treatment. Mice were sacrificed if the tu-
mor weight exceeded 10% of the body mass, the mice lost
10% body weight, when the tumor reached a tumor size of
1350 mm3 or at the end of the experiment.
Histology
Mice implanted s.c. with murine B16BL6 melanoma were
injected with 3 mg/kg Dox-TSL or Dox-CTSL and liposomes
were allowed to circulate for 5 h. Then, HT for 1 h at 42°C
was applied to trigger drug release. Organs and tumors were
taken out 24 h after liposome injection. PBS without HT was
used as a control.
Statistics
In vivo biodistribution study was analyzed by Mann–Whitney
test and results with p-value≤0.05 were considered statistically
significant.
RESULTS
Pharmacokinetics and Biodistribution of Dox-TSL
and Dox-CTSL
The characteristics of the liposomes used here have been
reported previously (7). In order to understand Dox clear-
ance from circulation and its distribution in healthy or-
gans and tumors, pharmacokinetic and biodistribution
profiles of Dox in TSL or CTSL were followed (Fig. 1a
and b) under NT or HT conditions. At both NT and HT
conditions, the trend of Dox-TSL and Dox-CTSL clear-
ance from circulation was similar. At NT condition
(Fig. 1a), Dox from TSL and CTSL seemed to clear from
circulation fast in the first 1 h (52 and 47% remaining
Dox respectively). After 2 h of liposome circulation, there
were ~20% remaining Dox from both formulations. At
later time points (4, 6, 24 h) there was barely any Dox
present in circulation from TSL whereas there were 11%
Dox left from CTSL after 4 h of circulation. Considering
the biodistribution of Dox (Fig. 1c and d), at both NT and
HT conditions, there was a significant uptake of Dox from
the two formulations in spleen as it was significantly
higher for Dox from CTSL than TSL under HT condi-
tions (19.7 v/s 6% ID/g). Similar high Dox accumulation
in the kidneys was observed from the two formulations,
which was slightly increased upon HT conditions for TSL
but significantly increased for CTSL (7.6 to 12.4%ID/g).
Dox accumulated in the liver was slightly higher for
CTSL than for TSL under NT (4.7%ID/g v/s 2.7%ID/
g respectively). However, under HT conditions there was
an increase in delivered Dox from CTSL to the liver than
TSL (6.7% ID/g v/s 3.7%ID/g respectively). The higher
Dox uptake in spleen and liver from CTSL is due to most
probably opsonization of CTSL by proteins in these or-
gans. There was a minimal uptake of Dox from TSL and
CTSL in the heart, lungs and muscle upon NT and HT.
No Dox was detected in the brain from neither of the
formulations. At NT, the tumor uptake of Dox was simi-
lar for the two formulations. However, the application of
initial HT for 1 h at 41°C was able to cause ~2.3 fold
increased Dox amount to the tumor from TSL (1.7 v/s
4% ID/g) and 3.4 fold increased Dox to the tumor from
CTSL (2 v/s 6.8%ID/g). The initial HT treatment was
able to significantly increase (1.7 fold) Dox delivery to
tumor from CTSL compared to TSL.
630 Dicheva et al.
Tumor Growth Control and Survival of Mice
with B16BL6 Tumors
The efficacy of either Dox-TSL orDox-CTSLwas followed in
B16BL6 tumor bearing mice upon either NT or HT condi-
tions (Fig. 2a and b). HT itself showed a tremendous effect on
tumor growth (A and B). HT effect on the tumor growth was
comparable to TSL without HT. Interestingly, HT added to
CTSL decreased significantly tumor growth compared to
their effect on the tumor growth without HT. HT applied to
TSL did not add to inhibiting tumor progression. However,
the combination of liposomes and HT showed the highest
therapeutic effect. In the CTSL plus HT group, four out of
eight mice survived 12 days post-treatment whereas in the
TSL plus HT group, five out of six mice survived 10 days
post-treatment (C). In comparison, the group with CTSL
without HT survived only 8 days post-treatment (four out of
eight mice). Therefore, HT applied to mice treated with
CTSL increased their survival by 4 days. HT added to TSL
did not increase mice survival. HT added to PBS increased
survival only with 1 day.
Tumor Growth Control and Survival of Mice with LLC
Tumors
The efficacy of Dox-TSL and Dox-CTSL was followed in
mice implanted with LLC tumor model based on two differ-
ent treatment schedules:—preheating of the tumor for 1 h at
41°C followed by cooling it down for 15 min, injection of
liposomes, allowed to circulate for 5 h and subsequently ap-
plication of HT for 1 h at 42°C or:—the same treatment
skipping the preheating phase (Fig. 3). The preheating phase
was used to induce extravasation of liposomes. Treatment
with initial HT additionally to one HT treatment decreased
significantly tumor growth and prolonged survival only in the
case of Dox-CTSL (Fig. 3a and b). Survival was increased with
8 days (from 10 to 18 days). The effect on tumor growth of
Dox-TSL and Dox-CTSL with preheat were similar. Dox-
Fig. 1 Pharmacokinetics (a and b) and biodistribution (c and d) of Dox-TSL and Dox-CTSL in B16BL6 tumor bearing mice upon NTor initial HTconditions. At
NTcondition (a and c), mice were injected with 3 mg/kg Dox and blood sampling was performed at the indicated time points and organs collected 24 h after
liposomes injection. At HTcondition (b and d), tumors in mice were preheated for 1 h at 41°C and cooled down for 15 min, in order to allow for liposome
extravasation. Then, liposomes were injected at 3 mg/kg Dox and blood samples were collected up to 24 h, after which the organs were removed. The Dox
concentration in the blood and organs was analyzed by HPLC. Six animals were used per group. *Mann–Whitney test, p-value ≤0.05.
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CTSL with preheat increased the survival of mice with 2 days
(from 16 to 18 days) compared to Dox- TSL with preheat.
Preheating phase did not add to one HT treatment in
inhibiting tumor growth or increasing survival when Dox-
TSL or PBS alone were used.
Control on Treatment Toxicity in Mice with B16BL6
Tumors and LLC Tumors
Dox-TSL and Dox-CTSL effect on mice regarding their tox-
icity was tested by measuring body weight every other day
after treatment. In B16BL6 tumor model, PBS and PBS plus
HT treatment did not show any toxicity on mice. All the other
treatments with or without HT demonstrated toxicity only in
the first 2 days after treatment shown by drop in body weight.
However, after 2 days, body weight of all mice from all treat-
ment groups was recovered and remained stable until death
(Fig. 4a). Similarly, in LLC tumor model, there was an initial
body weight loss in all the tratment groups, which was recov-
ered in 2 to 4 days after treatment and remained stable until
death of mice (Fig. 4b).
IntravitalMicroscopy on Liposome andDox distribution
in tumors
In order to know which formulation of liposomes will be more
effective in killing the tumor, we followed the retention of
liposomes and Dox in tumor. Images of B16BL6 window
chamber tumor bearing mice were taken up to 5 days after
DiD labelled Dox-CTSL or Dox-TSL injection (Fig. 5). Im-
ages show that the two formulations extravasated from circu-
lation 24 h after liposome injection and can be found vascu-
lature or associated with it in the case of CTSL. Liposome and
Dox clearance from the tumor progressed over time as can be
concluded from decreased DiD and Dox fluorescent signal in
the tumor. Remarkably, there was still an abundant amount
Fig. 2 Mice implanted with B16BL6 tumors were injected with 3 mg/kg Dox-TSL or Dox-CTSL. In the HT group, liposomes were allowed to circulate for 5 h,
after which HTat 42°C for 1 h was applied to trigger drug release. (a) Individual tumor growth curves from all mice in all treatment groups. (b) Efficacy of all
treatments. (c) Survival of mice upon different treatments.
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Fig. 3 Mice implanted with LLC tumors were either preheated for 1 h at 41°C followed by 15 min of cooling down to body temperature or were not
preheated. Then, they were injected with 3 mg/kg Dox-TSL or Dox-CTSL, after which the liposomes were allowed to circulate for 5 h at NT. After that, HTat
42°C for 1 h was applied to trigger drug release. (a) Individual tumor growth curves from all mice in all treatment groups. (b) Efficacy of all treatments. (c) Survival
of mice upon different treatments.
Fig. 4 Body weight of the treated mice was followed every other day after treatment until death. (a) Body weight of mice with B16BL6 tumors. (b) Body weight
of mice with LLC tumors.
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of liposomes left in the tumor tissue even 120 h after injection
of the two formulations. The Dox clearance from the tissue
was faster for TSL (B) than for CTSL (A) which is suggestive
for higher retention of CTSL in tumors.
IHC of Tumor and Normal Tissues
Dox-CTSL plus mild HT for 1 h at 42°C caused interstitial
haemorrhage in s.c. murine B16BL6melanoma.Oedema was
also seen in this treatment group. No obvious pathology was
obserbed in tumors frommice from the other groups. None of
the treatments showed any toxicity to the normal organs as
concluded from the morphology of the spleen, kidneys and
liver compared to the control PBS treatment (Fig. 6).
DISCUSSION
Thermosensitive liposomes loaded with Dox in combination
with HThave emerged as a promising treatment approach for
cancer patients (39–41). The aim of this approach is to in-
crease drug levels in the tumor, thus increasing therapeutic
efficacy. Several TSL formulations have been developed in
the last two decades differing in their serum stability,
thermosensitivity and ligand targeting (17,20,42–46). Lipo-
some formulations having stability at 37°C and fast release
kinetics at HT will offer best results in the clinic. For optimal
application, stability of liposomes at physiological tempera-
tures is very important in order to prevent premature drug
release. Despite the many efforts made until now (42,47,48),
the search for the best liposomal formulation is still ongoing.
Reasons for this can be the limited tumor accumulation and
specificity of liposomal nanoparticles, low drug bioavailability
due to its stable entrapment and lack of control of drug re-
lease. Many novel approaches have been proposed in the past
years to tackle these issues and thereby improve liposomal
chemotherapy.We used two key approaches for improvement
in this study being cell-specific targeting and temperature-
controlled drug release. On one hand, CTSL are positively
charged and will recognize negatively charged anionic sites on
the membranes of tumor endothelial cells and tumor cells. In
this way both tumor vasculature and tumor cells will be
targeted. Once in contact, cationic lipids fromCTSLwill bind
to anionic molecules on tumor or endothelial cells. This bind-
ing might evoke a receptor-mediated endocytosis, leading to
CTSL internalization. Differently, CTSL are thermosensitive
and when HT is applied drug release is forced, thus generat-
ing bioavailable drug either outside or within the targeted cell.
Fig. 5 Doxorubicin and liposome
retention in B16BL6 tumors
implanted in window chamber
bearing mice. Mice were injected
with 5 mg/kg Dox-CTSL (a) or
Dox-TSL (b) labelled with DiD.
Liposomes were allowed to
circulate for 5 h, after which HTwas
applied to the tumor for 1 h. Mice
were observed up to 120 h in order
to follow up the Dox and liposome
clearance from the tumor.
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The intracellularly released drug will then be transported to the
nucleus where it can exert its therapeutic effect, while drug
released outside the cell can either diffuse away or enter the cell.
Although previous studies focused on determination of
Dox levels in tumors and blood and Al-Jamal et al. described
the pharmacokinetics and biodistribution of different TSL
(37), insight into biodistribution and pharmacokinetics of
targeted TSL is lacking. Therefore, this study focuses on un-
derstanding these together with the therapeutic efficacy of our
CTSL.
The pharmacokinetic behavior of Dox-TSL and Dox-
CTSL was investigated with or without HT. In accordance
with Al-Jamal et al. (37), local HT did not affect the blood
kinetics of Dox from TSL and CTSL and it was cleared from
circulation in a similar manner both under NT and HT con-
ditions (Fig. 1a and b). After 1 h of liposome circulation under
NT, ~50% of the encapsulated Dox was cleared, after which
its concentration gradually decreased. This pharmacokinetic
profile of CTSL proves that targeting does not cause faster
liposome and subsequently drug clearance from circulation
and it is in accordance with Dicheva et al. (43) showed by
intravital microscopy that the concentration of fluorescently
labelled CTSL and TSL in circulation was similar. Figure 5
confirms that targeting does not lead to faster liposomal clear-
ance and shows that targeting contributes to a longer liposo-
mal and drug retention in tumors. Dox from CTSL showed
the only presence in circulation 4 h after injection, whereas
Dox from TSL was completely cleared. At later time points,
Dox levels were below detection in any of the formulations for
both NT and HT.
Biodistribution studies showed that the highest uptake per
gram of tissue of Dox-TSL and Dox-CTSL was in the spleen
and the kidneys followed by the liver (Fig. 1b). This observa-
tion is also in accordance with Al-Jamal et al. (37) showing the
highest uptake of their formulations in liver and spleen. The
high spleen and liver uptake are due to the fact that these
organs are part of the mononuclear phagocyte system
(MPS), which is responsible for filtering out foreign particles
from the blood circulation (49). There was no explanation
why kidneys had an increased Dox uptake at both NT and
Fig. 6 H&E staining of s.c. murine
B16BL6 melanoma tissues (a) in
tumor rim or tumor center and in
normal tissues (kidney, liver and
spleen) (b) treated with PBS, Dox-
TSL or Dox-CTSL under HT.
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HT conditions. Interestingly, HT increased Dox from CTSL
in spleen, kidneys and liver. As expected and in accordance
with Al-Jamal et al. (37), there was a little Dox uptake from the
two formulations under NT and HT in heart and lungs and
no uptake in brain and the leg muscle close to the heated
tumor. The absence of Dox in the leg muscle shows that the
heating was restricted only to the tumor. There was no differ-
ence in tumor uptake of Dox under NT from both formula-
tions showing that targeting does not contribute to increased
drug uptake at this condition. However, when initial HT for
1 h at 41°Cwas applied, there was an increased Dox uptake in
the tumor from both formulations, which is likely due to in-
creased extravasation of liposomes upon HT and therefore
their higher accumulation at the tumor site. Additionally,
Dox concentration from CTSL in the tumor was significantly
higher compared to TSL, which is most likely due to the
targeting nature of CTSL causing a higher accumulation of
the carrier in the tumor and subsequently increased drug
delivery.
In B16BL6 tumor model, HT itself had a tremendous ef-
fect in decreasing tumor growth (Fig. 3) but also increased
survival as compared to only PBS treatment. HT as an addi-
tive treatment to liposomes had a great effect on CTSL in
reducing tumor progression compared to TSL. In this case,
the survival was increased from 8 to 12 days, whereas in the
case of TSL the survival was not increased. There was not a
significant difference in tumor growth inhibition between
mice treated with Dox-TSL HT and Dox-CTSL HT, which
shows that in this tumor model the targeting does not play a
role in reducing the tumor volume compared with a non-
targeted formulation.
As the efficacy study with B16BL6 did not show the benefit
of using targeted thermosensitive liposomes in inhibiting tu-
mor growth, LLC tumor model was included in a pilot study
where two HT treatments were used—an initial mild HT at
41°C for 1 h to induce permeable tumor vasculature for lipo-
some extravasation and; a second heat to trigger drug release
(50). It was recently reported by Li et al. that a temperature of
41°C for 1 h can cause significant liposome extravasation in
multiple murine and human tumor models (14). As seen in
Fig. 3, the twoHT treatments led to reduced tumor growth by
Dox-CTSL compared to one HT treatment. The two HT
treatments were most efficacious for Dox-CTSL showing in-
creased survival from 10 to 18 days. Preheating phase had no
effect on TSL and PBS when compared to one HT treatment.
Interestingly, histology demonstrated that only CTSL plus
HT could cause hemorrhage and edema in the treated mice.
This observation is in accordance with Dicheva et al. (43) dem-
onstrating massive vessel destruction at 24 h after liposomal
injection when CTSL are used in combination with HT. In
the treated tumor models, HT showed the highest effect in
tumor suppression as an additive to Dox-CTSL compared to
Dox-TSL. This might be a result of its higher stability in
serum leading to an increased levels of released drug upon
HT. Another factor contributing to it might be that HT in-
creases CTSL binding to endothelial cells (45) leading to its
higher retention and effectiveness in tumor growth inhibition.
However, more comprehensive studies about liposome phar-
macokinetics are necessary. Interestingly, two HT treatments
might have a better treatment result with targeted liposomes
than one HT treatment.While intravascular release approach
is considered to provide better results with non-targeted lipo-
somes, the results presented here indicate a possible applica-
tion for the so-called two step approach where HT is used to
open up tumor vessels and to trigger release from targeted
liposomes.
CONCLUSION
Targeting of TSL did not lead to increased clearance of
CTSL from circulation compared to TSL. Initial HT condi-
tion increasedDox uptake in tumors fromCTSL compared to
TSL. Efficacy study in B16BL6 tumor model demonstrated
that HT had a significant effect on CTSL on tumor inhibition
and prolonged survival. Efficacy study in LLC tumors showed
that twoHT treatments hold promises for successful therapeu-
tic efficacy.
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